Objective: The aim of the study was to compare the hematologic toxicity of gemcitabine between fixed-dose rate (FDR) infusion and 30-minute standard infusion in the treatment of malignancy. Methods: The 25 malignancy patients confirmed by histopathology or cytology received single-agent gemcitabine or gemcitabine in combination with other chemotherapeutic agents. These patients were randomly divided into gemcitabine 1000 mg/m2 on d1, d8 at a rate of 10 mg/m2/min arm (FDR arm) or 30 min arm (standard arm), every 21 days one cycle. Hematologic toxicity was evaluated at the end of each cycle. Results: The 13 of 25 patients received gemcitabine FDR therapy, a total of 28 cycles was completed, and 32 cycles in the others (12 of 25 patients) with the standard arm. All patients were evaluable for hematologic toxicity. The result showed that the grades 3-4 leucopenia was significantly different between the two arms (14.3% vs 0, P < 0.05), and no significant differences of neutropenia, thrombocytopenia and hemoglobin suppression of grades 3-4 (14.3% vs 3.1%, 10.7% vs 3.1%, 3.6% vs 9.4%, P > 0.05, respectively) were observed between the two arms, no grade 4 of hemoglobin suppression was observed. Conclusion: Hematologic toxicity of gemcitabine therapy at a fixed-dose rate for malignancy is tolerable. Objective: The aim of the study was to compare the hematologic toxicity of gemcitabine between fixed-dose rate (FDR) infusion and 30-minute standard infusion in the treatment of malignancy. Methods: The 25 malignancy patients by histopathology or cytology received single- The patients were randomly divided into gemcitabine 1000 mg / m2 on d1, d8 at a rate of 10 mg / m2 / min arm (FDR arm) or 30 min arm (standard arm), gemcitabine or gemcitabine in combination with other chemotherapeutic agents every 21 days one cycle. Hematologic toxicity was evaluated at the end of each cycle. Results: The 13 of 25 patients received gemcitabine FDR therapy, a total of 28 cycles was completed, and 32 cycles in the others (12 of 25 patients) with The standard arm. All patients were evaluable for hematologic toxicity. The result showed that the grades 3-4 leucopenia was significantly different between the two arms (14.3% vs 0, P <0.05), and no significant differences of neutropenia, thromboc ytopenia and hemoglobin suppression of grades 3-4 (14.3% vs 3.1%, 10.7% vs 3.1%, 3.6% vs 9.4%, P> 0.05, respectively) were observed between the two arms, no grade 4 of hemoglobin suppression was observed. Conclusion: Hematologic toxicity of gemcitabine therapy at a fixed-dose rate for malignancy is tolerable.